BioTuesdays

Roth starts Hepion Pharma at buy; PT $9

Hepion Pharmaceuticals

Roth Capital Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $9 price target. The stock closed at $2.95 on Nov. 6.

“Hepion brings a laser focus on liver disease, combined with scientific expertise in a promising direct anti-fibrotic mechanism,” writes analyst Yasmeen Rahimi. “At its core, Hepion is liver-focused and we believe led by an all-star cyclophilin inhibitor and NASH team.” 

The company acquired CRV431, a promising cyclophilin inhibitor, from a June 2016 merger with Ciclofilin Pharma, and is led by CEO Robert Foster and his team from Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP). More recently, liver guru Dr. Stephen Harrison joined as consultant medical director to lead the NASH program. 

Ms. Rahimi said cyclophilins have a direct hand in fibrosis and inflammation, making this mechanism of action ideal for NASH. Cyclophilins catalyze the cis-trans peptide bond transition vital to proper protein folding. Three cyclophilins are implicated in the liver: cyclophilin A (CsA) contributes directly to collagen formation in stellate cells; cyclophilin B directs collagen cross-linking; and cyclophilin D controls the mitochondrial pore, a gatekeeper for energy balance.

“With this in mind, we point out that CRV431 is a small molecule based on cyclosporin A (natural cyclophilin inhibitor) but with optimized chemistry, including changes that eliminate CsA’s immunosuppression and increase cyclophilin affinity 10-fold,” Ms. Rahimi said. CRV431 also has anti-fibrotic, anti-inflammatory and anti-oxidant effects. 

“With five NASH mouse models reporting consistent anti-fibrotic effects, SAD results support CRV431 PK and safety, and we believe de-risks the ongoing MAD trial in the lead up to a Phase 2 NASH biomarker study expected in the first half of 2020,” she added.

Ms. Rahimi said upcoming NASH catalysts include a readout expected in the first half of 2020 for the 28-day CRV431 MAD study in healthy volunteers and initiation of a one-month, Phase 2 biomarker study also in the first half in F2-F3 NASH patients. 

“Able to execute on the NASH pilot study with optimized dosing (from prior readouts), we believe Hepion is well-positioned to translate preclinical results into robust potency on fibrosis biomarker (especially Pro-C3 and TIMP-1) in just a single month,” she said.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.